Rationale: Congenital heart disease (CHD) is among the most common birth defects. Most cases are of unknown pathogenesis.
C ongenital heart disease (CHD) is the most frequent birth defect, affecting ≈7 in 1000 live births 1 and is a significant cause of childhood morbidity and mortality. 2 Rare Mendelian disorders, specific chromosomal abnormalities, and copy number variants (CNVs) are known to explain a subset of CHD cases, [2] [3] [4] but the cause of >80% of CHD remains unexplained.
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The application of evolving technologies that detect structural variation throughout the genome has demonstrated a considerable contribution of CNVs to CHD. Early cytogenetic studies recognized an increased prevalence of de novo chromosomal abnormalities in syndromic patients with CHD, observations that were replicated and extended to nonsyndromic CHD with successive generations of CNV detection technologies including array comparative genomic hybridization and low-density single nucleotide polymorphism (SNP) arrays. [3] [4] [5] [6] [7] [13] [14] [15] [16] [17] [18] [19] Using these techniques, researchers have demonstrated significant burden of large de novo CNV in some specific CHD lesions. Such CNVs are reported to occur in 13.9% of infants with single ventricles compared with 4.4% in controls, 13 in 10% of nonsyndromic tetralogy of Fallot (TOF) compared with 4% of controls, 5 and in 12.7% children with hypoplastic left heart syndrome compared with 2% of controls. 19 Among different CHD lesions, the frequency of large de novo CNVs is similar. 19 Although many large CNVs are unique to a single patient with CHD, several are recurrent in CHD cohorts. A 3-Mb 22q11.2 deletion is the most common recurrent de novo CNV associated with syndromic conotruncal defects and is found overall in ≥10% of TOF, 20, 21 35% of truncus, and 50% of interrupted aortic arch type B cases. 22 Recurrent de novo CNVs in patients with CHD reported in multiple studies also occur at chromosomes 1q21.1, 3p25.1, 7q11.13, 8p23.1, 11q24-25, and 16p13.11. 5, 19 The identification of CHD loci that are altered by CNVs provides opportunities to elucidate disease pathogenesis. However, discerning the causal gene(s) and inferring critical networks and pathways that cause or contribute to CHD has been difficult because low-resolution technologies used in many studies (array comparative genomic hybridization and low-density SNP arrays) typically define large CNVs (>100 kb) involving many genes. To address these issues, we capitalized on 2 independent strategies, high-density SNP genotyping arrays (Illumina Omni-1.0 and 2.5M) and whole exome sequencing (WES), to detect smaller de novo CNVs in a family-based trio study of sporadic CHD cases with conotruncal, heterotaxy, and left ventricular outflow tract defects. 23 We compared CNVs found in CHD trios with those identified in healthy control trios. Through these analyses we sought to compare the robustness of genome-wide CNV detection using array-based and sequence-based technologies to determine whether there was an increased burden of smaller de novo CNVs in patients with CHD as was demonstrated with larger CNVs and to determine whether fewer genes altered by these CNVs enabled more precise detection of gene networks and pathways contributing to the pathogenesis of CHD. 
Methods Ethics Statement
Patient Cohorts
CHD probands and parents were recruited into the CHD Genes Study of the Pediatric Cardiac Genomics Consortium (CHD genes: ClinicalTrials.gov identifier NCT01196182) as previously described, 23 using protocols approved by institutional review boards of each institution. Trios selected for this study had no history of CHD in first-degree relatives. CHD diagnoses were obtained from echocardiograms, catheterization, and operative reports; extracardiac findings were extracted from medical records and included dysmorphic features, major anomalies, noncardiac medical problems, and deficiencies in growth or developmental delay. The pathogeneses for CHD were unknown; patients with previously identified cytogenetic anomalies or pathogenic CNVs identified through routine clinical evaluation were excluded. Whole blood samples were collected and genomic DNA extracted. CHD trios were studied by SNP arrays (n=414) or by WES (n=356), including a subset (n=233) that was analyzed by both methods. The distribution by CHD lesions in patients genotyped by arrays was 403 (61%) left ventricular obstruction, 197 (30%) conotruncal defect, 49 (7%) heterotaxy, and 12 (2%) other cardiac diagnoses (Online Table  I ). The distribution by CHD lesions in patients studied by WES was 284 (46.1%) left ventricular obstruction, 235 (38.1%) conotruncal defects, 78 (12.7%) heterotaxy, and 19 (3.1%) with other cardiac diagnoses (Online Table II) .
Control trios were the unaffected sibling and parents of a child with autism who were consented and recruited through the Simons Simplex Collection. CNVs were identified in the same way in the control trios as in the cases using SNP arrays (n=814) or WES (n=872), including a subset (n=385) analyzed by both methods. [24] [25] [26] Additional data on the distribution and prevalence of previously reported CNVs in the general population were derived from the Database of Genomic Variants (http://dgv.tcag.ca) and from 649 deidentified control subjects who had participated in an unrelated psychiatric case-control study, genotyped on the same high-density SNP array platforms at the same genotyping center as the CHD probands (438 on the Illumina Omni-1M and 211 on the Illumina Omni-2.5M). These controls were used only to prioritize the de novo CNVs identified by SNP array methods that were selected for confirmation analyses. 27 Samples with high inbreeding coefficients that were duplicated or had sex mismatches and trios with Mendelian errors >1% were removed from analyses. We started with 1536 genotyped samples (512 trios), including 561 on the Illumina Omni-1M and 969 on the Illumina Omni-2.5M. Four hundred sixty-one trios had the same array version for all family members. On completion of these quality control procedures, 1245 samples, including 447 genotyped on the Illumina Omni-1M and 798 on the Illumina Omni-2.5M high-density SNP array platforms, were taken forward for analysis, constituting 415 complete trios (Online Table III) .
Nonstandard Abbreviations and Acronyms
Three groups (Children's Hospital of Philadelphia, Harvard, and Yale) independently analyzed genotyping data using slightly different algorithms to detect putative de novo CNVs. For each of the 3 independent analyses, CNVs were called for each subject using PennCNV 28 with the hidden Markov model algorithm and custom-made population frequency of B-allele and guanine cytosine model files. CNVs were called when ≥10 consecutive probes demonstrated consistent copy number change. The PennCNV detect_cnv --trio option was used to boost transmission probability of CNV calling for initially de novo scored CNVs. Fragmented CNV calls were merged using clean_cnv. All candidate CNVs were visually inspected to ensure the appropriate pattern of LRR and B-allele frequency was consistent with the CNV call. In addition, Gnosis, 24 QuantiSNP, 29 and Nexus (biodiscovery.com) were used to increase specificity. De novo CNVs were prioritized for quality by genomic length, number of probes, confidence score based on signal strength, 50% overlap of ≥2 algorithms, low parental origin P value using infer_snp_allele, and visual B-allele frequency/LRR review. CNVs with a minor allele frequency >1% were removed, leaving rare CNVs. All putative de novo CNVs were experimentally evaluated by digital droplet polymerase chain reaction (ddPCR; Online Figure I ), and only validated CNVs are reported.
De novo CNV loci that were previously reported as pathogenic were defined by reported recurrence in ≥2 publications using independent data. Although some of the CNVs reported here overlap with previously reported CNVs in CHD patients based on review of the literature, 30 they do not meet our frequency constraint for previously reported pathogenic de novo CNV loci.
CNV Identification and Variant Calling From WES Data
WES data from 356 CHD trios were analyzed for de novo CNVs (Online Table II ). WES samples were captured with the Nimblegen SeqCap Exome V2 chemistry and sequenced on the Illumina HiSeq 2000 platform as previously described. 31 Sequence reads were aligned to the human reference genome hg19 using Novoalign (http://novocraft.com), BWA (Burrows-Wheeler Aligner), 32 and ELAND (Efficient LargeScale Alignment of Nucleotide Databases). 33 Duplicates were marked with Picard (http://picard.sourceforge.net). Indel realignment and Base Quality Score Recalibration were done with Genome Analysis Toolkit (GATK). eXome Hidden Markov Model (XHMM) is an algorithm to detect exon-level copy number variation and assign CNV quality metrics 34 and was used at 4 of the Pediatric Cardiac Genetics Consortium analysis sites (Children's Hospital of Philadelphia, Harvard, Columbia, and Mount Sinai) to identify de novo CNVs (Online Figure II) . Candidate de novo CNVs were inspected visually. Putative de novo CNVs were prioritized for confirmation based on genomic length, low sequence depth variability, and low prevalence in the XHMM call set data (allele frequency<1%). All putative de novo CNVs were independently confirmed by ddPCR.
Single nucleotide variants (SNVs) and short insertions/deletions (indels) were called from the Novoalign alignment of WES trios using a pipeline derived from GATK version 2.7 best practices. 35 Briefly, aligned reads were first compressed using the GATK ReducedReads module, and variants were called on all CHD WES trios using the UnifiedGenotyper joint variant calling module. Identified variants were filtered using GATK variant quality score recalibration. Variants were annotated using SnpEff. 36 De novo SNVs and indels were independently confirmed using Sanger sequencing.
CNV Confirmation With ddPCR
Putative CNVs were experimentally confirmed with ddPCR, as previously reported, 37 using an 18-to 27-base pair FAM probe designed within each candidate CNV region, avoiding homopolymer runs or probes that began with G. A VIC probe targeting the RPP30 gene was used as reference. Reaction mixtures of 20-μL volume comprising ddPCR Master Mix (Bio-Rad), relevant forward and reverse primers and probe(s) and 100 ng of digested DNA were prepared, ensuring that ≈25% to 75% of the 10 000 droplets ultimately produced were positive for FAM or VIC signal. For de novo CNV confirmations, DNA from the patient with CHD and parents was used. After thermal cycling, plates were transferred to a droplet reader (Bio-Rad) that flows droplets single-file past a 2-color fluorescence detector. Differentiation between droplets that contain target and those that did not was achieved by applying a global fluorescence amplitude threshold in QuantaSoft (Bio-Rad). The threshold was set manually based on visual inspection at approximately the midpoint between the average fluorescence amplitude of positives and negative droplet clusters on each of the FAM and VIC channels. Confirmed CNV duplications had ≈50% increase in the ratio of positive to negative droplets as did the reference channel. Conversely, confirmed CNV deletions had approximately half the ratio of positive to negative droplets as did the reference channel.
Network Analysis
Three bioinformatic algorithms were used: Database for Annotation, Visualization and Integrated Discovery (DAVID), 38 Disease Association Protein-Protein Link Evaluator (DAPPLE), 39 and WebGestalt. 40 Four different gene lists derived from the de novo CNV loci were used (Online Table IV ). The lists were constructed as follows: (1) all genes contained within de novo CNV intervals, (2) published causative genes from previously reported CHD CNVs intervals in addition to all genes in novel CHD CNV intervals. Causal genes in previously reported CNV intervals included ELN (Williams syndrome), RAI1 (SmithMagenis syndrome), TBX1 (22q11 deletion), GATA4 (8p23.1 deletion), GJA5 (1q21.1 duplication), and NKX2.5 (5q35.1 deletion); (3) genes contained solely within novel CHD CNV intervals (eg, exclude genes from previously published CNVs); (4) genes contained within de novo CNV intervals that are highly expressed in the developing mouse heart (top quartile of all genes expressed E14.5 mouse heart). 31 We anticipated that genes in list 2 and list 4 would have increased specificity for CHD in comparison with genes in list 1 and that genes in list 3 would be biased toward new disease networks.
We expanded network analysis input gene lists by including both de novo CNV genes and de novo SNVs that were previously identified in CHD probands by WES. 31 Only de novo SNVs predicted to be deleterious (eg, loss of function [LOF]: nonsense, frame-shift, and splice site mutations and missense variants that alter highly conserved amino acid residues or predicted to be deleterious by SIFT [Sorting Intolerant from Tolerant] or PolyPhen2) were included in the expanded gene list. The additional gene lists included (5) all genes within a de novo CNV interval (eg, list 1) and protein-altering SNVs and (6) published causative genes from previously reported CHD CNVs intervals in addition to all genes in novel CHD CNV intervals (eg, list 2) and protein-altering SNVs.
Statistical Analysis
Burden calculations were done with a Fisher exact test computed in the R statistical computing environment. For analyses using DAVID, networks with an enrichment of genes affected by CNVs were assigned a P value with Benjamini and Hochberg correction for multiple testing with a false discovery rate of 0.05. In DAPPLE, type I error was controlled through permutation. P values of <0.05 were considered significant.
Results
Identification of De Novo CNVs
We studied 415 CHD trios genotyped by SNP arrays and 356 trios by WES analysis, including 233 trios studied by both methods. No trios had an affected first-degree relative, and the genetic cause of CHD in all studied children was unknown (Online Tables I and II) .
Sixty-five de novo CNVs identified in CHD cases were independently confirmed by ddPCR (Table 1) . De novo CNVs were identified in 51 unique probands (9.8%). These CNVs ranged in size from 0.1 kb to 12.8 Mb. Forty eight of these (76%) were <500 kb and half were smaller than 110 kb. The number of genes in the CNV intervals ranged from 1 to 175 with 42 (67%) having ≤5 genes. Four de novo intervals contained no genes. Six probands had 2 de novo CNVs, 2 had 3 CNVs and 1 had 4 CNVs.
The parental origin of deletion CNVs was determined when the haplotype of the remaining copy could be uniquely assigned to 1 parent. Seven de novo CNVs arose on maternal chromosomes and 10 on paternal chromosomes. The remainder could not be assigned because of uninformative or insufficient numbers of informative parent-of-origin SNPs.
Comparison of SNP Array and WES CNV Calling
To consider the accuracy of identifying de novo CNVs from SNP array data, we first considered a set of 40 highconfidence PennCNV de novo CNV calls that contained ≥10 adjacent SNPs, were >10 kb in length, and passed visual inspection. Among these 40 high-confidence putative CNVs, 40 were experimentally validated by ddPCR in the proband and 32 (80%) were experimentally confirmed to be de novo, representing a false-positive rate of 20%. For smaller de novo CNVs identified using the high-density array data, we considered a set of 97 high-confidence PennCNV putative de novo CNV calls based on 7 to 9 SNPs. Although 88% were experimentally validated by ddPCR in the proband, only 4 of the 97 (5%) were confirmed to be de novo.
From the WES data, we selected an initial set of 29 putative CNVs with a size range spanning 6 orders of magnitude from 530 bases in length (2 exons) to >8 Mb in length covering hundreds of exons. Twenty-six of the 29 CNVs (90%) confirmed experimentally to be de novo, representing a false-positive rate of 10%. The 3 false-positive CNVs included one 530-bp region that contained only 2 exon targets and 2 different inherited CNVs that were miscalled as de novo because both parents harbored CNVs at the locus. On the basis of these considerations, we restricted subsequent WES de novo CNV calls to those containing ≥3 exons and for which each parental data set contained no CNVs within the locus.
To evaluate false-negative rates of the 2 platforms and analyses, we tested our ability to detect 4 CNVs (2 22q11 deletions, 1 17p11 duplication, and 1 10q terminal deletion; Online Table V in clinical cases previously diagnosed with these CNVs). These 4 CNVs served as positive controls and were distinct from the Pediatric Cardiac Genetics Consortium cohort. Both the SNP array and the WES platforms detected each of these 4 large, clinically significant CNVs.
We also compared the results of de novo CNVs analysis from the 233 trios studied by both SNP array and WES. Among 42 confirmed de novo CNVs in these trios, 24% (10/42) were identified by both platforms, whereas 40% (17/42) were identified only with the SNP arrays and 35% (15/42) only by WES ( Figure 1 ). The recognized technical limitations of each platform prevented detection of some CNVs. For example, CNVs that occur exclusively in noncoding sequences are not captured by WES, whereas CNVs in coding or noncoding genomic regions where the SNP density is sparse can escape detection by SNP arrays.
From our studies, we deduced that de novo CNVs were accurately detected by arrays when ≥10 adjacent SNPs were affected or by WES when >3 adjacent exons were affected. In our data set, 29 of 42 CNVs fulfilled both of these criteria and should have been identified by both technologies (Figure 1 ). However, only 34% (10/29) of these ddPCR confirmed CNVs were identified by both platforms. SNP arrays uniquely identified 34% (10/29) and WES analyses uniquely identified 31% (9/29). Taken together, the false-negative rate of each methodology is ≈30% to 35%. Overall, the genome-wide analyses of de novo CNVs identified by SNP arrays were reasonably concordant with WES data, but each also identified complementary CNVs. The minimum CNV size that we reliably detected by SNP arrays was 10 kb and by WES was 1 kb although some smaller CNVs identified by these techniques were validated.
CNV Burden Analysis
The burden of de novo CNVs in CHD cases and control trios was initially compared using analyses from SNP arrays. De novo CNVs were assessed in 841 control trios, studied using the Illumina Omni-1M array to match the case trio array resolution and called using the PennCNV algorithm using computational parameters described previously. 24 Nine de novo ddPCR-validated CNVs were identified among 841 control trios. Twenty-two de novo ddPCR-validated CNVs were identified among 462 CHD trios with SNP arrays. These data define a significant burden of CNVs in CHD cases when compared with controls (odds ratio [OR], 4.6; Fisher P=7×10 -5 ; Table 2 ). After excluding 9 previously identified CHD-associated CNVs, the calculated burden of novel CNVs identified in CHD cases remained modestly significant (OR, 2.7; Fisher P=0.02).
To provide further support for this finding, we analyzed the burden of de novo CNVs that were identified by WES. WES in CHD cases and control trios were technically Table 2 ). Excluding the 6 de novo CNVs previously identified as CHD associated, we identified a similar OR and P value as in the SNP array data (OR, 2.3; Fisher P=0.03).
Our data identify an increased burden of CNVs, detected by SNP arrays or WES, in patients with CHD when compared with controls. We observed a larger mean size of de novo CNVs with increased burden in patients with CHD (3.6 Mb) than controls (495 kb; t test P=0.035) with the distribution of CHD CNVs skewed toward the largest CNVs identified in CHD cases. The median size of de novo CNVs from CHD cases (522 kb) was also significantly larger than controls (118 kb; Mann-Whitney P=0.028). Of the CNVs identified by SNP array that were capable of detecting CNVs outside of coding regions, there was a trend toward an increased number of de novo CNVs in controls that contained no coding exon (4/9) when compared with Pediatric Cardiac Genetics Consortium cases ( CNVs in 4 CHD probands (2 deletions and 2 duplications) at the BP1-BP2 15q11.2 locus that spans ≈225 kb (chr15: 22 836 000-23 062 000) were observed as recurrent de novo events (Online Figures III and IV) . Both patients with duplications (1-00192, 1-00315) and 1 with a deletion (1-00243) had left ventricular obstruction because of aortic coarctation. The remaining proband (1-01396) had TOF with pulmonary atresia. As there was no de novo CNV identified in this region among 814 and 872 control trios studied, respectively, by SNP arrays or WES, this locus has a significant burden of de novo CNVs in CHD cases (4/538 CHD versus 0/1301 controls; Fisher P=0.007). CNVs at the 15q11.2 locus were observed at low frequency (allele frequency<1%) in the Database for Genomic Variants. Among the 3 genes altered by this CNV (CYFIP1, NIPA1, and NIPA2), only CYFIP1 is highly expressed in the developing mouse heart. 31 CYFIP1 encodes the cytoplasmic FMR1-interacting protein 1, which has dual roles in inhibiting local protein synthesis and in promoting actin remodeling. 41 An earlier study observed an increased burden of inherited deletions in CHD cases at 15q11.2 1 and a recent article identified a single Genomic coordinates refer to hg19. APVS indicates absent pulmonary valve syndrome; ASD, atrial septal defect; CNV, copy number variant; CoA, coarctation of the aorta; CTD, conotruncal defect; DTGA, dextro-transposition of the great arteries; HLHS, hypoplastic left heart syndrome; HTX, heterotaxy; LVOT, left ventricular outflow tract obstruction; M, maternal chromosome; P, paternal chromosome; PA, pulmonary atresia; PS, pulmonary stenosis; TOF, tetralogy of Fallot; TriAtresia, tricuspid atresia; and VSD, ventricular septal defect. *Copy number: 1, deletion and 3, duplication. †Analysis: A, identified with single nucleotide polymorphism array and E, identified with whole exome sequencing. ‡De novo CNV loci that were previously reported as pathogenic. In addition, a recurrent CNV was observed to alter a novel locus at chromosome 2p13.3. A de novo 190-kb deletion was identified in a TOF proband (1-01536) and was maternally inherited in a proband with truncus arteriosus (1-01805) . No 2p13.3 CNV was found in control samples or in Database for Genomic Variants. Among 3 genes included in the CNV interval (ASPRV1, PCBP1, and PCBP1-AS1), only PCBP1 is highly expressed in the developing mouse heart. 31 PCBP1 encodes a major cellular poly(rC)-binding protein, which controls translation from mRNAs containing the differentiation control element. 42 In DECIPHER (Database of Chromosomal Imbalance and Phenotype in Humans using Ensembl Resources), patient 257771 with an atrioventricular canal defect had a 7-Mb overlapping deletion of 2p13.3, suggesting that this locus may also contribute to disease risk in CHD.
Integration of CNV and Sequence Data to Identify CHD Genes
To improve the identification of specific genes altered by CNVs that might cause or contribute to CHD, we searched the WES data for de novo, rare LOF variants in genes encoded in CNV intervals. We identified a terminal deletion of chromosome 11q24.2-q25, which causes Jacobsen syndrome in 1 patient with CHD (1-01486) with clinical manifestations typical of this dominant disorder (hypoplastic left heart, coarctation of the aorta, mitral and aortic valve atresia, strabismus, and short stature). ETS1 has been proposed as the critical CHD gene in the Jacobsen syndrome locus based on impaired ventricular development in an Ets1-null mouse. 43 WES analyses identified a de novo ETS1 frameshift mutation (chr11: 128 350 159GTCCT>G, c.1046_1049delAGGA [p.K349fs]) in another patient with CHD without the chromosome 11q24.2-q25 deletion with cardiac abnormalities observed in Jacobsen syndrome (hypoplastic left heart and mitral valve atresia). Our data provide the first human genetic evidence to suggest that ETS1 mutations contribute to the cause of cardiac malformations in Jacobsen syndrome.
We also assessed whether de novo CNVs in combination with a rare or novel deleterious variant on the other allele might produce recessive forms of CHD. One patient with CHD (1-01179) with a de novo 10q25-26 deletion also had a novel CTBP2 variant (p.R134W) on the remaining allele. The hemizygous variant that was absent from public genome databases 44, 45 is predicted to be damaging (Polyphen2 score of 0.998) and altered a phylogenetically conserved residue (PhyloP score=2.54). Cardiac abnormalities are present in approximately one third of patients with subterminal chromosome 10q deletions and recently CTBP2 was proposed as ; and an additional set of unpublished controls provided by State selected by the same criteria and sequenced as described in ref. 26 . Figure 2 . Network analysis of copy number variant (CNV) loci genes. Two networks of direct protein-protein interactions, (A) NKX2.5/Gata4 and (B) ETS1/JUN/TOP2A, were consistently identified in the DAPPLE (Disease Association Protein-Protein Link Evaluator) de novo CNV loci analysis. P values from the genes highly expressed in the developing heart, the most restrictive gene set list, are presented here. C, The ETS1/JUN/TOP2A network was significantly elaborated on by incorporating genes with deleterious de novo point mutations and indels in the whole exome sequencing analysis in addition to the CNV loci. Of note, 2 probands had de novo ETS1 variants (1 CNV and 1 frameshift), 2 probands had de novo SMAD2 variants (a splice site mutation and a highly conserved missense variant), and 2 probands had de novo ELN variants (both Williams syndrome CNVs). October 24, 2014 a candidate CHD gene. 46 The clinical manifestations of our patient, truncus arteriosus and right aortic arch, resemble the phenotypes identified in a Ctbp2-null mouse (failure of vascular remodeling and cardiac looping). 47 We suggest that CTBP2 sequence analyses in individuals with chromosome 10q deletions may identify additional variants in a subset of patients that modify phenotype.
Correlation of CHD Phenotypes and CNVs
The frequency of de novo CNVs was 10% among conotruncal anomalies, 6% among left-sided obstructive lesions, and 21% in heterotaxy. We observed a modest trend toward increased extracardiac manifestations, such as developmental delay in patients with de novo CNVs (Online Table VI ). Approximately 31% of all patients with CHD studied with SNP arrays or WES had extracardiac manifestations, whereas 40% (21/52; OR, 1.5; Fisher P=0.2) of patients with de novo CNVs had extracardiac features. This association has been found in some, 48 but not all, 19 previous studies, perhaps because of differences in the ages of the patients with CHD studied, methods of clinical data collection, and the definition of an extracardiac anomaly.
Gene Networks Affected by CNVs in CHD
We used pathway and network analysis with DAVID, 38 DAPPLE, 39 and WebGestalt, 40 using as input 4 different lists of genes encoded within all de novo CNV loci (Methods in the Online Data Supplement; Online Table  IV) . Initial gene lists contained (1) all genes encoded in a de novo CNV interval; (2) genes previously defined as causative with CNVs intervals plus all genes in novel de novo CNV intervals; (3) only genes contained within novel de novo CNV intervals; (4) all genes contained within de novo CNV intervals that are highly expressed (top 25%) in the developing heart. 31 DAVID identified enrichment of a gene pathway implicated in acetylation P<2.3×10 −4 , phosphoprotein P<3.9×10 −4 , and G-protein-activated inward rectifier potassium channel P<2.5×10 −2 (Benjamini-Hochberg corrected). WebGestalt implicated an enrichment of previously identified CHD genes, including ELN, NKX2.5, GATA4, and ZEB2, contributing to Gene Ontology processes: anatomic structure formation involved in morphogenesis P<0.03, cardioblast differentiation P<0.03, and septum secundum development P<0.02 (Benjamini-Hochberg corrected).
Using DAPPLE, we identified 2 additional subnetworks of direct protein/protein interactions that were consistently observed across 4 gene lists. Among genes encoded within CNVs that are highly expressed in the developing heart, a subnetwork consisting of NKX2.5 and GATA4 (P<0.1; Figure 2A ) and a subnetwork consisting of ETS1, JUN, TOP2A, and MKI67 (P<0.01; Figure 2B ) were identified. By further expanding the CNV gene lists to include genes with de novo LOF mutations, the ETS1/JUN/TOP2A subnetwork was significantly elaborated on and enriched (P<0.005). Each of these 3 genes was directly linked through protein-protein interactions to subnetworks containing ≥10 additional genes identified in either CNV or WES data sets. 31 This entire network incorporated >60 genes implicated in CHD ( Figure 2C ). Because the ETS1/ JUN/TOP2A subnetwork was robust to the specific de novo CNV gene list (criteria 2 above) and expanded with the addition of genes containing rare de novo LOF mutations, the data suggest that this subnetwork contains genes and pathways involved in CHD.
Discussion
We report whole-genome CNV analyses using complementary detection technologies in a large cohort of patients with CHD. CNV detection in WES has been investigated in schizophrenia 34 and autism, 49 but array-based and sequence-based strategies have not previously been directly compared, and our data highlight the differences between array-based and sequence-based strategies to detect de novo CNVs. By defining small CNVs with high resolution and integrating these findings with WES data that identified rare deleterious mutations, we identified novel de novo CNVs and genes involved in the pathogenesis of CHD. We show that 9.8% (53/538) of patients with CHD without a previously identified genetic pathogenesis have rare de novo CNVs. We previously demonstrated that 10% of patients with CHD in our cohort have de novo single nucleotide or small insertion/deletion mutations in genes highly expressed in the developing heart that are likely to be damaging. 31 None of the patients with CHD with rare de novo CNVs reported here carry these variants. Even if all the de novo CNVs and de novo predicted pathogenic sequence variants we have identified were causative, we do not yet know the pathogenesis for the majority of CHD subjects in our study.
Our detection rate of ≈10% de novo CNVs in patients with CHD is equivalent to previous studies, 5, 19, 48 despite identifying small CNVs. Had we not excluded patients with known pathogenic CNVs identified through clinical care, we expect that de novo CNVs would have been identified in ≈15% of patients with CHD, based on the prevalence of common de novo CNVs in CHD (eg, 7% of TOF with chromosome 22q11 deletions and 1% of TOF to 1q21 CNVs). In our study, these CNV loci accounted for <1% of CHD probands.
Despite these exclusion criteria, we identified a 4-fold increased frequency of rare de novo CNVs relative to the background frequencies of 1.2% (detected by SNP arrays) and 1.8% (detected by WES) of de novo CNVs in controls (P=7×10 -5 , P=4 ×10 −4 , respectively). Even after excluding previously defined CNVs, we still observed an ≈2-fold increase in novel rare de novo CNVs (P=0.02).
Because the OR of de novo CNVs in cases versus controls was 3.5 to 4.6, we estimate that between 50% and 70% of de novo CNVs observed in cases may be disease causing. The possibility exists that a higher percentage of de novo CNVs increase the risk of CHD but may not be sufficient to cause CHD without other contributing genetic or environmental factors. In addition, subtle anatomic defects in the heart may not have been diagnosed in the control group because controls were not systematically examined by echocardiogram. Overall, our evidence suggests a model in which de novo CNVs contribute to CHD.
The comparison of dense array-based platforms and WES analyses to detect independently validated CNVs indicates that each strategy identifies only ≈70% of the CNVs that should be within the detection limitations of each technology. As such, these 2 CNV methodologies provide substantial complementary information. An important corollary to this conclusion is that previously published CNV analyses in human disease may have significantly underestimated the burden conveyed by these structural variants.
Among all confirmed de novo CNVs, 61% (41) were deletions and 39% (26) were duplications. The proportion of these classes of CNVs are not significantly different; whether the trend toward more CNV deletions in CHD is biologically meaningful or reflects greater sensitivity to detect deletions by these methods will require further analyses. De novo CNVs ranged in size from <1 kb to 12.8 Mb, with a median size of 110 kb. Thus, half of the independently confirmed CNVs were smaller than the reported detection limit of most previous studies. For example, 4 patients with CHD had 200-kb de novo CNVs on chromosome 15. Although the pathogenicity of the identified CNVs remains to be determined, we propose that the smaller CNVs involving fewer genes are particularly valuable in defining specific candidate CHD genes in comparison with larger CNVs that typically include many more candidates. The ability to detect small CNVs is helpful reliably, particularly if they fall within large CNVs previously identified and define a critical interval of overlap. For example, we identified 1 de novo CNV that only affected JUN and another that only altered TOP2A, 2 genes that were implicated by network analyses as interacting with transcription factors SMAD2, SMAD4, and ETS1, molecules that play important roles in cardiovascular development.
Although there is considerable complexity in CHD phenotypes, we observed no significant difference in the frequencies of rare de novo CNVs among distinct CHD subclassifications. Although patients with CHD and CNVs in our cohort were more likely to have extracardiac phenotypes (OR, 1.5), this trend fell short of significance. Whether this finding reflects shared developmental biological pathways among different organ systems or the possibility that CNVs perturb multiple genes that individually contribute to organ system development remains unknown.
We identified several de novo CNVs that affected established CHD genes, including GATA4 and GJA5. We also identified a patient with CHD and a deletion of chromosome 5q34-q35.2, encompassing NKX2-5. LOF NKX2-5 mutations are an established cause of CHD, 3, 5, 6, 11, 12, 50 and CNVs encompassing NKX2-5 have been previously recognized in CHD. 18, 51, 52 We identified recurrent de novo CNVs involving deletions or duplications at chromosome 15q11.2. As the proximal region of chromosome 15 is meiotically unstable because of the segmental duplications that serve as breakpoint hotspots, recurrent de novo events at this locus might reflect locus genomic instability. However, the excess burden of de novo CNVs at this locus in patients with CHD when compared with controls (Fisher P=0.007) suggests otherwise. The report of an excess burden of inherited deletions in patients with CHD at this locus 3 lends further evidence for pathogenicity although this study lacked information on inheritance. Because CNVs at chromosome15q11.2 CNV exhibit incomplete penetrance for both neuropsychiatric and CHD phenotypes, genes affected by this could participate in inherited and sporadic CHD.
Chromosome 15q11.2 deletions and duplications are implicated in neurodevelopmental disorders, including schizophrenia, intellectual disability, and autism. 53 19, 60 ) that link cardiac malformations and neurocognitive disorders. These (and other) genetic loci may explain, in part, the significant coexpression of heart and brain developmental phenotypes in many children.
By integrating CNV and sequencing data from WES, we also identified candidate genes within CNV regions that may cause dominant or recessive forms of CHD. We present the first human ETS1 LOF mutation that likely contributes to Jacobsen syndrome. We also identified a rare inherited and predicted deleterious CTBP2 missense variant that is hemizygous because of a de novo CNV deletion, associated with a CHD phenotype comparable with that observed in Ctbp2-null mice. Continued integration of CNV and sequence data should enable more comprehensive assessments of genetic causes of disease. The current study provides suggestive data, and sequencing large cohorts of patients with CHD for mutations in these 2 genes will be necessary to prove the role of these genes in CHD unambiguously.
Network analyses by DAPPLE was more successful in elucidating novel network biology than DAVID and WebGestalt, which rely heavily on previously annotated gene sets and are challenged by the addition of unrelated genes encoded with CNV intervals along with pathogenic genes. If pathogenic CNVs on average contain 1 main causal gene and ≈5 unrelated genes, then we might expect DAVID and WebGestalt to be less informative for CNV network analyses. 61 Conversely, DAPPLE, based on proteomewide protein-protein interaction data rather than previously curated gene lists, calculates P values through within-degree node-label permutation, which is more permissive to background noise. 39 DAPPLE network analysis reinforced the central role of transcriptional regulation in CHD. The identification of 1 network, including NKX2.5/GATA4, provided a robust positive control as protein-protein interactions and substantial contributions by these molecules to CHD are previously described. 62, 63 Direct protein-protein interactions between ETS1/JUN/TOP2A have also been reported, [64] [65] [66] but this network has not been previously implicated in CHD. In an expanded network analysis of these molecules that included rare LOF mutations identified from exome sequencing, JUN was linked to SMAD2 and SMAD4, molecules that participate in cardiac development through the transforming growth factor-β signaling pathway.
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We focused our current analysis solely on rare de novo CNVs. Because the pathogenesis of CHDs is known to be polygenic, and incomplete penetrance of genes for CHD has been previously described, future analyses of rare inherited CNVs may expand these findings.
The novel de novo CNVs we report should be considered provisional pending replication in independent studies. Replication of the overall effect and the magnitude of the risk of these identified variants is needed. Although it is not yet possible to draw a conclusion about whether any particular de novo CNV is causal, the identification of additional CNVs and mutations in specific genes within the CNV intervals will be required to validate the new loci identified here.
In summary, integration of high-resolution complementary platforms for CNV and sequence data on large numbers of patients with CHD has proven valuable to define the underlying genomic architecture of CHD and expand the genes and networks involved in cardiac development and is likely applicable to the study of other diseases.
